双鹭药业：董事兼董秘梁淑洁减持计划实施完成

Core Viewpoint - The announcement from Shuanglu Pharmaceutical indicates that the planned share reduction by the board secretary has been completed without affecting the company's control [1] Group 1: Share Reduction Details - The board secretary, Liang Shujie, planned to reduce holdings by up to 375,189 shares, representing no more than 0.0365% of the total share capital [1] - The actual reduction was completed with a total of 375,090 shares sold at an average price of 7.5454 yuan per share [1] - Post-reduction, Liang Shujie's holdings decreased to 1,125,669 shares, which is 0.1096% of the total share capital [1] Group 2: Compliance and Control - The share reduction complies with relevant regulations and does not lead to a change in the company's control [1]